Granules India has successfully completed a US FDA Current Good Manufacturing Practice (CGMP) audit at its Chantilly manufacturing facility. The regulatory inspection, conducted from March 30 to April 3, 2026, concluded with the pharmaceutical company receiving four Form 483 observations from the FDA.

FDA Audit Results

The audit results present a mixed but manageable regulatory outcome for Granules India. While the company received four Form 483 observations, significantly, no data integrity issues were reported during the inspection. This absence of data integrity concerns is particularly noteworthy, as such issues typically represent more serious regulatory violations that can impact manufacturing operations and product approvals.

Regulatory Compliance Status

Form 483 observations are issued by the FDA when inspectors identify conditions or practices that may violate FDA regulations. The observations received are related to procedural matters, and the fact that Granules India received only four observations without any data integrity issues suggests that the facility maintains acceptable manufacturing standards. This marks the second US FDA inspection at the Chantilly facility in the last one year.

Manufacturing Operations Impact

The completion of the FDA audit represents an important regulatory milestone for Granules India's Chantilly facility. The absence of data integrity issues indicates that the company's quality systems and documentation practices at the site meet FDA expectations. Granules remains committed to maintaining the highest standards of quality, safety, and regulatory compliance and will address the observations raised by the US FDA within the stipulated timelines.

The Chantilly facility is operated by Granules Pharmaceuticals, Inc., a wholly-owned subsidiary of Granules India Limited. This regulatory clearance supports the facility's continued operations and its ability to supply products to the US market.

Granules India has announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), has successfully concluded a US FDA inspection with a Voluntary Action Indicated (VAI) classification. The inspection of the manufacturing facility at Shamirpet, Telangana, was conducted between December 15 and 19, 2025, and is now officially closed with no regulatory action recommended.

FDA Inspection Details

The US Food and Drug Administration conducted a comprehensive current Good Manufacturing Practice (cGMP) and pre-approval inspection (PAI) of the oral solid dosage manufacturing operations at the Shamirpet facility. The Establishment Inspection Report (EIR) was subsequently issued, leading to the VAI classification.

Management Commentary

Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India Limited, emphasized the company's commitment to quality standards. "While receiving the classification is a step in the right direction, we recognize that quality is not a one-time milestone but an ongoing commitment. It will continue to remain a core pillar of utmost importance across all Granules sites, guiding our actions, investments, and culture every day," he stated.

Strategic Manufacturing Impact

The VAI classification strengthens Granules India's finished dosage manufacturing capabilities by enabling multi-site manufacturing for approved products. This development allows the company to leverage its manufacturing network more effectively while maintaining regulatory compliance across its facilities.

Regulatory Compliance Significance

A VAI classification from the FDA indicates that while some observations may have been noted during the inspection, they do not warrant immediate regulatory action. This outcome allows GLS to continue its manufacturing operations without major disruptions while maintaining its good standing with the US regulatory authority. The successful completion reinforces the subsidiary's adherence to pharmaceutical manufacturing standards and quality control systems required for the US market.